Next Article in Journal
Artificial Intelligence Computing at the Quantum Level
Previous Article in Journal
Deceptive Content Labeling Survey Data from Two U.S. Midwestern Universities
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Data Descriptor

Impact of p53 Knockout on Protein Data Set of HaCaT Cells in Confluent and Subconfluent Conditions

V. N. Orekhovich Research Institute of Biomedical Chemistry, 119121 Moscow, Russia
*
Author to whom correspondence should be addressed.
Submission received: 30 December 2021 / Revised: 25 January 2022 / Accepted: 17 February 2022 / Published: 23 February 2022

Abstract

:

Abstract

The immortalized keratinocytes, HaCaT, are a popular model for skin research (toxicity, irritation, allergic reactions, or interaction of cells). They maintain a stable keratinocyte phenotype and respond to keratinocyte differentiation stimuli. However, programs of stratification and expression of differentiation markers in HaCaT keratinocytes are aberrant. In HaCaT cells, there are two mutant p53 alleles (i.e., R282Q and H179Y) that contain gain-of-function (GOF) mutations resulting from spontaneous immortalization (mutp53). At the same time, mutp53 acts as a transcription factor and also affects the interaction of p63 protein with its transcription targets. Proteins of the p53 family are crucial for regulation of proliferation and differentiation processes in human keratinocytes, although the involvement of mutp53 in these processes is not fully clear. We present data sets obtained as a result of high-performance proteomic analysis of immortalized HaCaT keratinocytes with p53 knockout in two different states, subconfluent and confluent, which are characterized by different intensites of cell differentiation processes. To obtain the proteomic profiles of the cells, we applied LC-MS/MS measurements processed with MaxQuant software (version 1.6.3.4).

Dataset

http://www.proteomexchange.org/ (Project identifier: PXD030700)

Dataset License

CC-BY 4.0

1. Introduction

Proteins of the p53 family take an active part in the regulation of processes of proliferation and differentiation of human keratinocytes both in normal physiology and keratinization disorders [1,2]. It is noteworthy that some of p53-dependent genes, such as P21 and 14-3-3σ, are activated during keratinocyte differentiation [3]. In some studies, it has been demonstrated that psoriasis and atopic dermatitis, with aberrant differentiation of keratinocytes, are accompanied by an increase in p53 gene expression [4,5].
Another transcription factor of the p53 family is the p63 protein, coded by TP63, the master gene of keratinocyte differentiation. It plays a key role in epidermal development, where it is directly involved in the regulation of numerous target genes crucial for the implementation of the processes of keratinocyte proliferation, differentiation, and adhesion [1,6]. The features of the functioning of these proteins in the cells of the immortalized HaCaT keratinocyte cell line have been studied to a lesser extent. In HaCaT cells, there are two mutant TP53 alleles (i.e., R282Q and H179Y) that contain gain-of-function (GOF) mutations [7]. At least two mechanisms of the GOF of mutant p53 are known: it affects the functions of p63/p73 by inhibiting their binding to DNA [8], or it binds to new DNA sites by interacting with other transcription factors (NF-Y, E2F1, NF-KB, VDR, and p63) [9,10]. More than seven thousand DNA binding sites are known for Mutp53 in HaCaT cells [11]. In addition, in contrast to normal human keratinocytes, HaCaT cells mainly express the ΔN p63 isoform (synthesized from an internal promoter and lacks the N-terminal transactivation domain), and the TA isoform (with N-terminal transactivation domain) is practically not detected [12]. Since the HaCaT cell line is the most popular model of normal human keratinocytes, studying the functioning of p53 family proteins in these cells is important for understanding the limitations of this model system.
This study aimed to obtain data on the proteomic profile of HaCaT cells with knocked-out TP53 and WT HaCaT in two different states: subconfluent and confluent. It is known that when the confluent state is reached, the processes of differentiation of human keratinocytes turn out to be the most intense [13].

2. Data Description

The data set contained “RAW” files generated by high-throughput proteomic analysis of wild-type HaCaT keratinocytes (WT HaCaT) and p53 knockout HaCaT keratinocytes (dp53 HaCaT). Sample information is presented in Table 1. The data set included 16 biological samples. Data files are listed in Table 2.
Western blot was employed for knockout verification (Figure 1).
Comparison of confluent wild-type and dp53 mutant protein profiles resulted in the identification of 405 proteins. Out of them, 224 were identified in both samples and 181 were found either in WT or mutant. Meanwhile, the overall protein number for the nonconfluent pair (i.e., WT and dp53 mutant) was 803, including 398 common and 405 unique proteins. Using t-tests, statistically significant differences in the production level were found for nine and three proteins for confluent and nonconfluent cells, respectively. The common trend for both pairs was a significantly lower number of unique proteins (detected only in one condition) for the WT (9 vs. 153 and 32 vs. 373 for the confluent and nonconfluent samples, respectively).
In addition, the protein profiles of the confluent samples were compared with the respective nonconfluent ones. The common trend was a decreased number of produced proteins in the nonconfluent samples. Overall, 788 and 785 proteins were identified for WT and mutant samples, respectively. Out of them, 536 and 488 proteins were only found in confluent WT and dp53 mutant, respectively; whereas only 4 and 14 proteins were characteristic for the respective nonconfluent analogs. In addition, for the confluent/nonconfluent mutant pairs, 106 proteins with statistically significant expression were determined (Figure 2).
To evaluate the mutual influence of mutation and confluency onto protein profiles of cells, two-way ANOVA analysis was performed. Overall, 511 proteins were significant as an interception of these two parameters. Most of these significant proteins were involved in different cellular metabolic processes (32.5%) or related to cellular component organization or biogenesis (20.2%) (Figure 3). The STRING analysis of differently expressed proteins for confluent cells is presented in Figure 4.

2.1. Value of the Data

  • The data set presents wild-type and p53 knockout human immortalized HaCaT keratinocyte proteomes that can be examined to determine differences;
  • Provided data may be valuable to researchers developing in vitro skin models;
  • Provided data will be useful for scientists investigating epidermal stratification;
  • “RAW” data files are provided and can be processed by researchers using preferable bioinformatics tools and compared to their data.

2.2. Data Records

Proteomic data were deposited to the ProteomeXchange Consortium via the PRIDE partner repository (http://www.proteomexchange.org/Project, accessed on 29 December 2021, accession: PXD030700).

3. Materials and Methods

3.1. Reagents

Sodium chloride, taurocholic acid sodium salt (TCA), and acetonitrile were provided by Merck (Darmstadt, Germany). Formic acid was from ACROS Organics (Geel, Belgium), and tris-(2-carboxyethyl)-phosphine (TCEP), methanol, and trifluoroacetic acid (TFA) were from Fluka (Buchs, Switzerland). Modified trypsin was obtained from Promega (Madison, WI, USA). For cell cultivation, we used DMEM/F:12 medium (1:1), GlutaMAX, fetal bovine serum, PBS, and penicillin/streptomycin (all from Gibco, Waltham, MA, USA).

3.2. Cells and Culture Conditions

HaCaT cells were obtained from DKFZ, Heidelberg, and cultured in DMEM/F:12 medium (1:1, Gibco, Waltham, MA, USA) supplemented with 1% GlutaMAX (Thermo Fisher Scientific, Waltham, MA, USA), penicillin/streptomycin (100 UI/mL and 100 μg/mL, Gibco, Waltham, MA, USA), and 10% v/v fetal bovine serum (Gibco, Waltham, MA, USA). Cell cultivation was carried out in 25 cm2 tissue-treated flasks or 60 mm Petri dishes (Corning, Corning, NY, USA) with culture medium replaced fresh every two days. Cells were harvested by trypsinization after 3 day culture in 100% confluence for the confluent condition or after achieving 70% confluence for the subconfluent condition.

3.3. CRISPR/Cas TP53 Downregulation

Cas9n D10A from S. pyogenes was employed to perform TP53 gene knockout. PX461 (Addgene, #48140) encoding Cas9n (D10A), appropriate gRNAs, and the GFP reporter gene was used for transfection. The sequences of paired gRNA are listed below:
  • gRNA 1-GGAAGCTCCCAGAATGCCAG;
  • gRNA 2-GCATTGTTCAATATCGTCCG.
HaCaT cells were seeded at a concentration of 1 × 105 per mL of medium in 6-well plate 48 h prior to transfection and grown under standard conditions. The cells were transfected with PEI (0.5 mg/mL, Polysciences, Inc., #23966-1, Warrington, PA, USA) and 2 µg of each vector. After 2 days, cells expressing GFP were sorted via BD FACSAria III instrument (BD Biosciences, Franklin Lakes, NJ, USA) directly to 96-well plates and grown until clonal analysis.

3.4. Sequence Analysis

The p53 deficient clones were grown under standard conditions for 48 h up to a 70% confluence. Total DNA was isolated with the ExtractDNA Blood & Cells kit (Evrogen, Moscow, Russia, #BC111M). The area of alleged editing was amplified with the following primers:
  • F-AAAGTTCTGCATCCCCAGGAG;
  • R-GCAGTCAGATCCTAGCGTCG.
The Sanger sequencing was performed by Evrogen, Moscow, Russia. The quantitative assessment of genome editing was performed with TIDE software as described [14].

3.5. Western Blot

Verification of knockout was performed using 8% sodium SDS-PAGE, and 1 × 106 of wild-type and p53 knockout cells were harvested via trypsinization for Western blot analysis. The cell pellet was lysed in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, and pH 8.0).
The proteins were transferred onto PVDF membrane following immunoblotting with anti-p53 (clone BP-53-12, PrimeBioMed, Moscow, Russia) and anti-GAPDH (Abcam, ab9485, Cambridge, UK) antibodies as loading control. Alkaline phosphatase-conjugated secondary antibodies were used for primary antibodies recognition. The chemiluminescent reaction was detected via X-ray film.

3.6. Protein Extraction for MS Analysis

The cell pellets were lysed in 100 μL of lysis buffer (4% SDS in PBS, pH 7.4). The lysates were incubated under rotation at room temperature for 20 min following 5 min of incubation at 95 °C. The samples were cooled down and sonicated with Bandelin 2070 (Bandelin, Germany) by three 20 s cycles at 90% power. The methanol–chloroform method was applied for protein precipitation [15]. Briefly, 400 μL of methanol was added to the lysates. The mixtures were vortexed; then, 100 μL of chloroform and 300 μL of ddH2O were added. The mixtures were vortexed and centrifuged at 14,000× g for 2 min. The aqueous layer was discarded and 400 μL of methanol was added. The samples were mixed by vortex and centrifuged for 5 min at 14,000× g. The methanol was removed, and the pellets were speed-dried for 5 min at 45 °C with the Eppendorf Concentrator 5301 (Eppendorf, Hamburg, Germany).

3.7. Sample Preparation for MS Analysis

Protein concentrations were determined with the BCA assay kit (Pierce™ BCA Protein Assay Kit, Waltham, MA, USA). Protein extracts (50 μg) were diluted in 20 μL of denaturation buffer (5M urea, 1% TCA, 15% acetonitrile, 50 mM phosphate buffer at pH 6.3, and 300 mM sodium chloride). Then, 5 μL of 25 mM TCEP in 0.1 M ammonium bicarbonate was added to the mixtures followed by 30 min incubation in the dark. To quench the remaining IAA, 5 μL of 300 mM DTT in 0.1 M ammonium bicarbonate was added. The mixtures were diluted in 0.1 M ammonium bicarbonate to a final volume of 200 μL. Subsequently, trypsin in enzyme: protein ratio 1:50 was added for in-solution digestion. The samples were incubated overnight at 37 °C under rotation and centrifuged at 10 °C and 12,000× g for 10 min. Supernatants were collected and purified with C18 ZipTip following the supplier’s protocol [16]. Briefly, the columns were washed with 0.1% trifluoroacetic acid (TFA) in acetonitrile, then equilibrated twice with 0.1% TFA in ddH2O. The samples were applied to the ZipTips and washed thrice with 0.1% TFA and 5% methanol in ddH2O. The peptides were eluted by 70% acetonitrile with 0.1% formic acid.

3.8. LC-MS/MS Analyses

Peptides were separated via an Acclaim μ-Precolumn (0.5 × 3 mm, particle size of 5 μm, and an inner diameter of 75 μm; Thermo Scientific, Waltham, MA, USA). The peptide solution (1 μg of peptide in 1–4 μL of 0.1% formic acid) was loaded on the column directly. The peptide concentration was performed in the isocratic mode of Mobile Phase C (2% acetonitrile, 0.1% formic acid) at a flow rate of 10 µL/min for 4 min.
High-performance liquid chromatography (HPLC) was applied for peptide separation. The procedure was performed via Ultimate 3000 Nano LC System (Thermo Scientific, Waltham, MA, USA). C18 columns (Acclaim® PepMapTM RSLC with an inner diameter of 75 μm; Thermo Fisher Scientific, Waltham, MA, USA) were used for peptide separation. The peptides were eluted in a gradient mode. The gradient was formed by 0.1% formic acid (mobile phase A) and buffer B (80% acetonitrile, 0.1% formic acid) at flow rate of 0.3 μL/min. The columns were equilibrated by mobile phase A for 12 min with a subsequent increase in the buffer B concentration from 5% to 35% for over 95 min. Then, the buffer B concentration was increased to 99% (6 min). The columns were repeatedly washed with 99% buffer B and equilibrated with buffer A (7 min).
The MS analysis was performed in at least three technical replicates using a Q Exactive HF-X mass spectrometer (Q Exactive HF-X Hybrid Quadrupole-OrbitrapTM Mass Spectrometer, Thermo Fisher Scientific, Waltham, MA, USA). The analysis was performed under the following conditions: the capillary temperature was 240 °C and the ionizing voltage was 2.1 kV. The spectra were acquired at the 300–1500 m/z range at a resolution of 120,000 (MS). Tandem spectra were acquired at the 140–2000 m/z range at a resolution of 15,000 (MS/MS). The maximum integration for precursor and fragment ions was 50 and 110 ms, respectively. The AGC target for precursor and fragment ions were set to 1 × 106 and 2 × 105, respectively. An isolation intensity threshold of 50,000 counts was determined for the precursor’s selection. The top 20 precursors were chosen for fragmentation with high-energy collisional dissociation (HCD) at 29 NCE. Precursors with a charge state of +1 and more than +5 were rejected, and all measured precursors were dynamically excluded from triggering a subsequent MS/MS for 20 s.
Mass spectrometric measurements were performed using the equipment at the “Human Proteome” Core Facility of the Institute of Biomedical Chemistry (Russia, Moscow).

3.9. Protein Identification

Label-free quantitation using MaxQuant software (version 1.6.3.4) was applied to experimental data. Only proteins identified by two or more unique/razor peptides were considered for label-free quantitation. The identification was performed against a concatenated target/decoy version of the Homo sapiens complement of the UniProtKB (July 2021). The database search was performed under the following parameters: enzyme specificity—trypsin; maximum cleavages allowed—2; MS1 and MS2 tolerances—5.0 and 20 ppm, respectively; fixed modification—carbamidomethylation (Cys); variable modifications—N-terminal proteins acetylation and methionine oxidation (Met), false discovery rate estimated using the decoy hit distribution for peptide spectrum matches (PSMs); peptides and proteins identification—1.0%.

Author Contributions

Conceptualization: N.G.L. and A.L.R.; methodology: A.L.R., V.G.Z., M.N.K., D.S.L., D.D.R. and P.M.K.; investigation: V.G.Z., A.L.R., P.M.K., D.D.R., M.N.K., N.G.L. and O.V.T.; resources: A.L.R. and D.D.R.; data curation: V.G.Z. and D.D.R.; validation: A.L.R.; writing—original draft preparation: N.G.L., A.L.R., P.M.K., V.G.Z., D.D.R., M.N.K., D.S.L. and O.V.T.; writing—review and editing: N.G.L., A.L.R., P.M.K., D.D.R., M.N.K., D.S.L. and O.V.T.; supervision, N.G.L.; project administration: A.L.R. and N.G.L. All authors have read and agreed to the published version of the manuscript.

Funding

The work was conducted in the framework of the Russian Federation fundamental research program for the long-term period of 2021–2030.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Proteomic data were deposited to the ProteomeXchange Consortium via the PRIDE partner repository (http://www.proteomexchange.org/Project, accessed on 29 December 2021, accession: PXD030700).

Acknowledgments

Mass spectrometric measurements were performed using the equipment at the “Human Proteome” Core Facility of the Institute of Biomedical Chemistry (Russia, Moscow).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript or in the decision to publish the results.

References

  1. Truong, A.B.; Kretz, M.; Ridky, T.W.; Kimmel, R.; Khavari, P.A. P63 Regulates Proliferation and Differentiation of Developmentally Mature Keratinocytes. Genes Dev. 2006, 20, 3185–3197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Botchkarev, V.A.; Flores, E.R. P53/P63/P73 in the Epidermis in Health and Disease. Cold Spring Harb. Perspect. Med. 2014, 4, a015248. [Google Scholar] [CrossRef] [PubMed]
  3. Westfall, M.D.; Mays, D.J.; Sniezek, J.C.; Pietenpol, J.A. The Delta Np63 Alpha Phosphoprotein Binds the P21 and 14-3-3 Sigma Promoters in Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations. Mol. Cell. Biol. 2003, 23, 2264–2276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Baran, W.; Szepietowski, J.C.; Szybejko-Machaj, G. Expression of P53 Protein in Psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat. 2005, 14, 79–83. [Google Scholar]
  5. Batinac, T.; Zamolo, G.; Jonjić, N.; Gruber, F.; Petrovecki, M. P53 Protein Expression and Cell Proliferation in Non-Neoplastic and Neoplastic Proliferative Skin Diseases. Tumori 2004, 90, 120–127. [Google Scholar] [CrossRef] [PubMed]
  6. Pellegrini, G.; Dellambra, E.; Golisano, O.; Martinelli, E.; Fantozzi, I.; Bondanza, S.; Ponzin, D.; McKeon, F.; De Luca, M. P63 Identifies Keratinocyte Stem Cells. Proc. Natl. Acad. Sci. USA 2001, 98, 3156–3161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Lehman, T.A.; Modali, R.; Boukamp, P.; Stanek, J.; Bennett, W.P.; Welsh, J.A.; Metcalf, R.A.; Stampfer, M.R.; Fusenig, N.; Rogan, E.M. P53 Mutations in Human Immortalized Epithelial Cell Lines. Carcinogenesis 1993, 14, 833–839. [Google Scholar] [CrossRef] [PubMed]
  8. Xu, J.; Reumers, J.; Couceiro, J.R.; De Smet, F.; Gallardo, R.; Rudyak, S.; Cornelis, A.; Rozenski, J.; Zwolinska, A.; Marine, J.-C.; et al. Gain of Function of Mutant P53 by Coaggregation with Multiple Tumor Suppressors. Nat. Chem. Biol. 2011, 7, 285–295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Cordani, N.; Pozzi, S.; Martynova, E.; Fanoni, D.; Borrelli, S.; Alotto, D.; Castagnoli, C.; Berti, E.; Viganò, M.A.; Mantovani, R. Mutant P53 Subverts P63 Control over KLF4 Expression in Keratinocytes. Oncogene 2011, 30, 922–932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Neilsen, P.M.; Noll, J.E.; Suetani, R.J.; Schulz, R.B.; Al-Ejeh, F.; Evdokiou, A.; Lane, D.P.; Callen, D.F. Mutant P53 Uses P63 as a Molecular Chaperone to Alter Gene Expression and Induce a Pro-Invasive Secretome. Oncotarget 2011, 2, 1203–1217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Martynova, E.; Pozzi, S.; Basile, V.; Dolfini, D.; Zambelli, F.; Imbriano, C.; Pavesi, G.; Mantovani, R. Gain-of-Function P53 Mutants Have Widespread Genomic Locations Partially Overlapping with P63. Oncotarget 2012, 3, 132–143. [Google Scholar] [CrossRef] [PubMed]
  12. Jung, Y.-S.; Qian, Y.; Yan, W.; Chen, X. Pirh2 E3 Ubiquitin Ligase Modulates Keratinocyte Differentiation through P63. J. Investig. Dermatol. 2013, 133, 1178–1187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Fuchs, E. Scratching the Surface of Skin Development. Nature 2007, 445, 834–842. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Brinkman, E.K.; Chen, T.; Amendola, M.; van Steensel, B. Easy Quantitative Assessment of Genome Editing by Sequence Trace Decomposition. Nucleic Acids Res. 2014, 42, e168. [Google Scholar] [CrossRef] [PubMed]
  15. Wessel, D.; Flügge, U.I. A Method for the Quantitative Recovery of Protein in Dilute Solution in the Presence of Detergents and Lipids. Anal. Biochem. 1984, 138, 141–143. [Google Scholar] [CrossRef]
  16. Rappsilber, J.; Mann, M.; Ishihama, Y. Protocol for Micro-Purification, Enrichment, Pre-Fractionation and Storage of Peptides for Proteomics Using StageTips. Nat. Protoc. 2007, 2, 1896–1906. [Google Scholar] [CrossRef] [PubMed]
Figure 1. p53 expression in HaCaT cells by Western blot. WT—wild type HaCaT; dp53—p53 knockout HaCaT.
Figure 1. p53 expression in HaCaT cells by Western blot. WT—wild type HaCaT; dp53—p53 knockout HaCaT.
Data 07 00027 g001
Figure 2. Venn diagram of identified proteins. The numbers of proteins detected are indicated by numbers. WT sub—wild-type HaCaT in the subconfluent state; WT conf—wild-type HaCaT in the confluent state; dp53 sub—p53 knockout HaCaT in the subconfluent state; dp53 conf—p53 knockout HaCaT in the confluent state.
Figure 2. Venn diagram of identified proteins. The numbers of proteins detected are indicated by numbers. WT sub—wild-type HaCaT in the subconfluent state; WT conf—wild-type HaCaT in the confluent state; dp53 sub—p53 knockout HaCaT in the subconfluent state; dp53 conf—p53 knockout HaCaT in the confluent state.
Data 07 00027 g002
Figure 3. Gene Ontology analysis by biological function of proteins significant for the interaction effect (p < 0.05) determined by two-way ANOVA analysis. The samples were categorized based on the presence of mutation and confluency.
Figure 3. Gene Ontology analysis by biological function of proteins significant for the interaction effect (p < 0.05) determined by two-way ANOVA analysis. The samples were categorized based on the presence of mutation and confluency.
Data 07 00027 g003
Figure 4. STRING analysis of differently expressed proteins for confluent cells.
Figure 4. STRING analysis of differently expressed proteins for confluent cells.
Data 07 00027 g004
Table 1. Information about the studied cell samples and the number of repeats.
Table 1. Information about the studied cell samples and the number of repeats.
Cell TypeWT HaCaT
Subconfluent
dp53 HaCaT
Subconfluent
WT HaCaT
(100% Confluence, 72 h)
dp53 HaCaT
(100% Confluence, 72 h)
Number of samples4444
Technical repeats per sample3–5333
Table 2. Data set description.
Table 2. Data set description.
SampleFile NameTypeSize (Mb)
WT 72 h s1_TR1110821CKP_LNRA01.rawRAW792
WT 72 h s1_TR2110821CKP_LNRA01_210811225153.rawRAW702
WT 72 h s1_TR3110821CKP_LNRA01_210812002917.rawRAW771
WT 72 h s2_TR1110821CKP_LNRA02.rawRAW890
WT 72 h s2_TR2110821CKP_LNRA02_210812045125.rawRAW812
WT 72 h s2_TR3110821CKP_LNRA02_210812062849.rawRAW787
WT 72 h s3_TR1110821CKP_LNRA03.rawRAW657
WT 72 h s3_TR2110821CKP_LNRA03_210812105056.rawRAW700
WT 72 h s3_TR3110821CKP_LNRA03_210812122818.rawRAW690
WT 72 h s4_TR1110821CKP_LNRA04.rawRAW710
WT 72 h s4_TR2110821CKP_LNRA04_210812165027.rawRAW679
WT 72 h s4_TR3110821CKP_LNRA04_210812182749.rawRAW707
dP53 72 h s1_TR1110821CKP_LNRA05.rawRAW763
dP53 72 h s1_TR2110821CKP_LNRA05_210812224958.rawRAW711
dP53 72 h s1_TR3110821CKP_LNRA05_210813002725.rawRAW724
dP53 72 h s2_TR1110821CKP_LNRA06.rawRAW737
dP53 72 h s2_TR2110821CKP_LNRA06_210813044935.rawRAW678
dP53 72 h s2_TR3110821CKP_LNRA06_210813062700.rawRAW676
dP53 72 h s3_TR1110821CKP_LNRA07.rawRAW670
dP53 72 h s3_TR2110821CKP_LNRA07_210813104909.rawRAW684
dP53 72 h s3_TR3110821CKP_LNRA07_210813122634.rawRAW664
dP53 72 h s4_TR1110821CKP_LNRA08.rawRAW711
dP53 72 h s4_TR2110821CKP_LNRA08_210813164846.rawRAW757
dP53 72 h s4_TR3110821CKP_LNRA08_210813182610.rawRAW715
WT subconf. s1_TR1110821CKP_LNRA09.rawRAW689
WT subconf. s1_TR2110821CKP_LNRA09_210813224817.rawRAW683
WT subconf. s1_TR3110821CKP_LNRA09_210814002539.rawRAW690
WT subconf. s2_TR1110821CKP_LNRA10.rawRAW671
WT subconf. s2_TR2110821CKP_LNRA10_210814044742.rawRAW690
WT subconf. s2_TR3110821CKP_LNRA10_210814062506.rawRAW679
WT subconf. s3_TR1110821CKP_LNRA11.rawRAW646
WT subconf. s3_TR2110821CKP_LNRA11_210814104709.rawRAW656
WT subconf. s3_TR3110821CKP_LNRA11_210817210241.rawRAW850
WT subconf. s3_TR4110821CKP_LNRA11_210817224002.rawRAW789
WT subconf. s3_TR5110821CKP_LNRA11_210818001729.rawRAW797
WT subconf. s4_TR1110821CKP_LNRA12.rawRAW799
WT subconf. s4_TR2110821CKP_LNRA12_210818043938.rawRAW771
WT subconf. s4_TR3110821CKP_LNRA12_210818061703.rawRAW755
dP53 subconf. s1_TR1110821CKP_LNRA13.rawRAW757
dP53 subconf. s1_TR2110821CKP_LNRA13_210818103910.rawRAW761
dP53 subconf. s1_TR3110821CKP_LNRA13_210818121633.rawRAW774
dP53 subconf. s2_TR1110821CKP_LNRA14.rawRAW696
dP53 subconf. s2_TR2110821CKP_LNRA14_210818163844.rawRAW1054
dP53 subconf. s2_TR3110821CKP_LNRA14_210818181609.rawRAW1043
dP53 subconf. s3_TR1110821CKP_LNRA15.rawRAW1144
dP53 subconf. s3_TR2110821CKP_LNRA15_210818223820.rawRAW1079
dP53 subconf. s3_TR3110821CKP_LNRA15_210819001551.rawRAW1077
dP53 subconf. s4_TR1110821CKP_LNRA16.rawRAW1045
dP53 subconf. s4_TR2110821CKP_LNRA16_210819043801.rawRAW1046
dP53 subconf. s4_TR3110821CKP_LNRA16_210819061530.rawRAW1062
SEARCH.rarSEARCH1011
checksum.txtOTHER0.0008
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rusanov, A.L.; Romashin, D.D.; Kozhin, P.M.; Karagyaur, M.N.; Loginov, D.S.; Tikhonova, O.V.; Zgoda, V.G.; Luzgina, N.G. Impact of p53 Knockout on Protein Data Set of HaCaT Cells in Confluent and Subconfluent Conditions. Data 2022, 7, 27. https://doi.org/10.3390/data7030027

AMA Style

Rusanov AL, Romashin DD, Kozhin PM, Karagyaur MN, Loginov DS, Tikhonova OV, Zgoda VG, Luzgina NG. Impact of p53 Knockout on Protein Data Set of HaCaT Cells in Confluent and Subconfluent Conditions. Data. 2022; 7(3):27. https://doi.org/10.3390/data7030027

Chicago/Turabian Style

Rusanov, Alexander L., Daniil D. Romashin, Peter M. Kozhin, Maxim N. Karagyaur, Dmitry S. Loginov, Olga V. Tikhonova, Victor G. Zgoda, and Nataliya G. Luzgina. 2022. "Impact of p53 Knockout on Protein Data Set of HaCaT Cells in Confluent and Subconfluent Conditions" Data 7, no. 3: 27. https://doi.org/10.3390/data7030027

Article Metrics

Back to TopTop